TCGA-IQ-A61G-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- MYC_TARGETS_V1+0.590
- MYC_TARGETS_V2+0.520
- DNA_REPAIR+0.440
- E2F_TARGETS+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- MTORC1_SIGNALING+0.360
- PANCREAS_BETA_CELLS+0.350
- G2M_CHECKPOINT+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- ANGIOGENESIS-0.440
- HEDGEHOG_SIGNALING-0.430
- WNT_BETA_CATENIN_SIGNALING-0.400
- UV_RESPONSE_DN-0.370
- APICAL_SURFACE-0.360
- MYOGENESIS-0.330
- ALLOGRAFT_REJECTION-0.300
- APICAL_JUNCTION-0.280
- IL6_JAK_STAT3_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.849 |
| 2 | SRR8518329 | — | E | 0.845 |
| 3 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.833 |
| 4 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.829 |
| 5 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.828 |
| 6 | TCGA-BB-A5HY-01A-11R-A28V-07 | — | — | 0.822 |
| 7 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.816 |
| 8 | c6c161fd-9f0a-4ad5-96ba-b9ce811348fc | — | — | 0.811 |
| 9 | 8027196b-a80b-4759-872d-b72c98905451 | — | — | 0.806 |
| 10 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |